CD274 and neoplasm: GSK3β induces PD-L1 glycosylation to block the binding of b-TrCP to PD-L1, which inhibits PD-L1 phosphorylation and proteasomal degradation of PD-L1, thereby promoting PD-L1 expression and tumor immune evasion [66,70].